Additional Therapeutics and Peptides
TB006
An investigational drug with the potential to Reverse Dementia including Alzheimer’s disease
What is TB006?
TB006 is an investigational drug developed by TrueBinding (www.truebinding.com). In their Phase 2a clinical trial, patients who received TB006 for one month demonstrated signs of symptom reversal and improvements in memory and cognition. While TrueBinding is planning a Phase 2b trial in 2025, the drug is available to patients through compassionate use or early access. We are pleased to offer this innovative treatment to patients at Colorado Concierge Functional Medicine through the Expanded Access Program.
Please be aware that, as TB006 is still in the investigational stage, the benefits of the drug cannot be guaranteed for everyone. However, if you or your loved ones are suffering from dementia and have exhausted other treatment options, TB006 may offer promising new hope. To learn more, please schedule a consultation with Dr. LaPerriere.
How Does TB006 Work?
TB006 It works by binding to and lowering amounts of Galectin-3, a different mechanism than any of the currently approved Alzheimer’s medications. Galectin-3 binds to amyloid beta and acts like glue causing amyloid beta proteins to stick to one another and form larger plaques. These plaques then deposit in the tissue between neurons blocking signals and leading to cognitive impairment. In addition, Galectin-3 is proinflammatory and activates the brain’s immune system (microglial cells) leading to neural inflammation and nerve cell damage/destruction. Galectin-3 is generally very high in the brains of patients with Alzheimer’s disease. TB006 prevents Galectin-3 from attaching to amyloid beta (blocking amyloid plaque formation) and prevents it from causing microglial activation. In doing so, TB006 may potentially decrease the amount of beta amyloid plaques and lower inflammation allowing nerve cells to heal and function more optimally.
How Do I Get Access to TB006?
TB006 is currently undergoing clinical trials and is not yet FDA approved. There are two ways to obtain TB006. One option is through participation in a clinical trial; however, not everyone meets the eligibility criteria, and there is possibility of getting enrolled into placebo group.
The alternative is through the Expanded Access Program (EAP). The FDA allows eligible patients to access investigational treatments when there is no satisfactory alternative treatment available. TB006 was approved for compassionate use (EAP) for dementia since June 2023.
How Much Does TB006 Cost?
If you enroll in and are accepted into a clinical trial, then the medication is free. However, there is a chance to be randomized into placebo group.
If you decide to obtain TB006 through the Expanded Access Program, you need to be aware that this medication is expensive. The price of the medication includes the manufacturing cost of the drug, the physician/clinic fees for administering and monitoring the treatments, and charges for exams, imaging, labs that are needed as part of the EAP program.
Eligibility Criteria
Since TB006 is still under investigation we can only administer the medication to those who meet certain eligibility criteria.
You must be diagnosed with Alzheimer’s disease (or other form of dementia)
You must be at least 55 years of age
You must have cognitive disability due to your current condition
You must have failed at least one other dementia medication
You must be unable or ineligible to enroll in another clinical trial.
If you feel you meet the above criteria and are interested in learning more about TB006 please reach out to COCFM to discuss details about fees, testing, and structure of the EAP program.
